MESOTHELIOMA CASE
Second-line treatment with Pemetrexed (Alimta)

This is an abstract of an article published at PubMed by the NIH on the subject of second-line treatment of mesothelioma using Pemetrexed (Alimta).

Malignant Pleural Mesothelioma is regarded as a tumour, which lacks chemo-sensitivity. However, patients are able to benefit from a first line chemotherapy, as indicated in a currently published randomised study. Here is the case of a 75-year-old patient diagnosed with malignant pleural mesothelioma for four years. After a first-line therapy with Gemcitabine/Oxaliplatin, partial remission was assessed. 15 months later a distinct progress was detected.

After a second-line therapy with Pemetrexed a sound partial response could be determined radiologically and clinically. This case history is supposed to exemplify that patients with malignant pleural mesothelioma should not only be considered for a first-line therapy, but that a second-line therapy may also be offered to a certain group of patients. The new substance Pemetrexed (Alimta) offers an excellent alternative with a very good efficacy profile and a favourable spectrum of side effects.

For legal information about mesothelioma and a free evaluation of your mesothelioma complaint, please fill out the form on this page.